Ryota Kominami

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Medicine, Oncology, Pharmacology +17

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya et al. · Investigational New Drugs · 2019 · 53 citations

Pharmacy, Oncology, Pharmacotherapy +16

Design of and rationale for the Japan Diabetes compREhensive database project based on an Advanced electronic Medical record System (J-DREAMS)

Takehiro Sugiyama, Kengo Miyo, Tetsuro Tsujimoto et al. · Diabetology International · 2017 · 51 citations · Full text

Computing, Biomedical Informatics, Health Informatics +14

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto et al. · Clinical Lung Cancer · 2020 · 45 citations

Life Sciences, Immunology, Oncology +14

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto et al. · BMC Cancer · 2021 · 33 citations · Full text

Medicine, Oncology, Pharmacotherapy +17